Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · IEX Real-Time Price · USD
2.240
-0.030 (-1.32%)
At close: Mar 27, 2024, 4:00 PM
2.460
+0.220 (9.82%)
After-hours: Mar 27, 2024, 6:53 PM EDT
Company Description
Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company.
The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming.
It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022.
Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.
Eterna Therapeutics Inc.
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Sanjeev Luther |
Contact Details
Address: 1035 Cambridge Street, Suite 18a Cambridge, Massachusetts 02141 United States | |
Phone | (212) 582-1199 |
Website | brooklynitx.com |
Stock Details
Ticker Symbol | ERNA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000748592 |
ISIN Number | US1140822099 |
Employer ID | 31-1103425 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Sandra M. Gurrola | Principal Financial and Accounting Officer and Senior Vice President of Finance |
Sanjeev Luther | Chief Executive Officer, President and Director |
Dorothy J. Clarke | General Counsel and Director |
Megan Yung | Chief Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 22, 2024 | 8-K | Current Report |
Mar 18, 2024 | 10-K/A | [Amend] Annual report |
Mar 14, 2024 | 10-K | Annual Report |
Feb 16, 2024 | 8-K | Current Report |
Jan 31, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 24, 2024 | 424B3 | Prospectus |
Jan 22, 2024 | EFFECT | Notice of Effectiveness |
Jan 19, 2024 | 8-K | Current Report |
Jan 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 17, 2024 | UPLOAD | Filing |